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Edited by Miguel De la RosaAbstract We demonstrate the utility of normal mode analysis
in correctly predicting the binding modes of inhibitors in the
active sites of matrix metalloproteinases (MMPs). We show
the accuracy in predicting the positions of MMP-3 inhibitors
is strongly dependent on which structure is used as the target,
especially when it has been energy minimized. This dependency
can be overcome by using intermediate structures generated
along one of the normal modes previously calculated for a given
target. These results may be of prime importance for further in
silico drug discovery.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Matrix metalloproteinases (MMPs) constitute a large family
of secreted zinc-dependent proteases that degrade components
of the extra-cellular matrix (ECM) [1]. They play a fundamen-
tal role in many physiological and pathological processes that
involve connective tissue remodelling, including tumor angio-
genesis, diﬀerentiation and metastasis [1–4]. The production
and activity of many MMPs have been correlated with almost
all types of cancers. Therefore, MMPs are important therapeu-
tic targets and the search for eﬃcient inhibitors represents an
important ﬁeld of investigation [5,6].
Among MMPs, MMP-3 has been extensively studied and
many structures are available describing the unbound enzyme
(PDB: 1CQR) [7] and diﬀerent inhibitor-bound forms. Among
the latter, we note the availability of the complex between
MMP-3 and its physiological inhibitor, TIMP-1 (1UEA) [8].Abbreviations: NMA, normal mode analysis; MMPs, matrix metall
proteinases; TIMPs, tissue inhibitors of MMPs; ECM, extra-cellul
matrix; SD, steepest descent; ABNR, adopted basis Newton–Raphso
PDB, protein data bank; RMSD, root mean square deviation
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ieties. PuMany other structures also describe the MMP-3 bound to
piperazine (1D8F) [9], carboxylic acid (1HY7) [10], thiazepine
(1D5J) [11] and pyrimidine based inhibitors (1G4K) [12]. All
these inhibitors chelate the catalytic zinc ion and also ﬁll a
hydrophobic cavity in close proximity to the metal (S1 0 cavity).
In the uninhibited enzyme structure, the S1 0 cavity is com-
pletely covered by Tyr223, while in the protein–inhibitor com-
plexes, the inhibitors displace this residue in order to ﬁt into
the cavity.
Molecular (in silico) dockings are now tools widely used in
drug design whether for spotting possible lead compounds or
optimizing protein–drug interactions. In many current studies,
molecular docking involves the prediction of ligand conforma-
tion and orientation within a rigid target binding site. When an
X-ray crystal structure of the target is available, virtual high-
throughput screening experiments can also be used to identify
new hits by docking the 3D structures of molecules contained
in a database.
In the case of MMP-3, using the crystal structure of the
unbound enzyme is not suitable for docking experiment since
the S1 0 cavity is narrower than in the bound form. On the
other hand, using a structure from one of the available
protein–inhibitor complexes could inﬂuence the docking
results because the S1 0 cavity may be altered due to the pres-
ence of the corresponding ligand. To eliminate this bias, the
ligand can be removed and the empty receptor submitted to
energy minimization, molecular dynamics, and/or other mole-
cular mechanics techniques. However, such methods when
applied to the empty protein can lead to signiﬁcant structural
modiﬁcations resulting into inappropriate structures for dock-
ing experiment (e.g. those in which the binding site is closed).
Thus, choosing an appropriate structure of the target for
docking is not an easy task and requires particular attention.
A closely related problem in computational drug design is
the diﬃculty of treating the ﬂexibility of the target explicitly
[13,14]. The use of only a single, rigid structure of the target
can considerably reduce the chances of identifying new mole-
cules that bind to the active site. Such a problem was recently
addressed for MMPs [15]. Diﬀerent approaches can be used to
overcome this problem, including new algorithms that con-
sider partial ﬂexibility of the target [16]. Another approach is
to use molecular dynamics simulations [17]. Recently, receptor
ﬂexibility in ligand docking was also considered using normal
mode analysis (NMA) through a measure of relevance on a
given region of interest [18].blished by Elsevier B.V. All rights reserved.
Table 1
Cross RMSD table of the MMP-3 structures used for the study
1UEA 1D8F 1G4K 1HY7 1D5J
1UEA 0 1.85 1.77 1.73 1.79
1D8F – 0 0.54 0.37 0.51
1G4K – – 0 0.41 0.55
1HY7 – – – 0 0.56
1D5J – – – – 0
The RMSD were computed on the main chain atoms. The structure
1UEA is the most divergent from the others. This structure was used
for NMA.
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MMP-3 catalytic domain from 1UEA. We visually inspected
the 25 lowest frequency modes of vibration. As expected the
ﬁrst few modes presented the most collective motions, of which
only one aﬀected the binding-site cavity in a clear opening–
closing fashion (mode number 2). Although other modes also
modulated the geometry of the binding-site cavity, their eﬀects
were not as pronounced and therefore only mode 2 was
selected for subsequent analysis. No further measure of rele-
vance was deemed necessary such as that employed in Ref.
[18]. Conformational search along additional modes or in com-
bination may provide advantages in general but did not prove
necessary in this case.
Using Flexx and Gold, two of the most eﬃcient and com-
monly applied docking programs, we show that simply using
the energy-minimized structure of MMP-3 from 1UEA [8] as
the target indeed leads to unreliable positions of all of the
ligands from the 1D8F, 1HY7, 1D5J and 1G4K complexes.
On the contrary, structures obtained from NMA allowed us
to dock correctly the various ligands using these programs.
We show that this strategy signiﬁcantly improved the dock-
ing results and highlights the interest of applying NMA to
drug design.2. Materials and methods
2.1. Normal modes calculation
The MMP-3 catalytic domain structure considered for the NMA
was taken from the MMP-3:TIMP-1 complex (1UEA) [8]. Zinc ions
were included as given in the PDB structure and the calculations were
performed after removal of the ligand from the active site. The hydro-
gen atoms were ﬁrst built and the whole structure was energy mini-
mized using the CHARMM program [19] and the force ﬁeld
PARAM22 [20] by using successively steepest descent (SD) and
Adopted Basis Newton–Raphson (ABNR) algorithms. Harmonic
constraints were applied to all the atoms, whose force constants were
progressively decreased from 250 to 0 kcal mol1 A˚2 during SD min-
imization. A ﬁnal minimization with all constraints removed was per-
formed using ABNR until a root mean square energy gradient of
106 kcal mol1 A˚1 was reached. The normal modes were computed
with the DIMB method [21] as implemented in CHARMM. For each
system, the lowest frequency modes were computed with a convergence
criterion of 104 on eigenvectors. Electrostatic interactions were trea-
ted with a r-dependent dielectric constant and a switch function ap-
plied between 10.0 and 12.0 A˚. Less than 5 h CPU-time were
required on a linux PC 3.4 GHz/2 Go RAM to obtain the description
of the 100 lowest frequencies normal modes of MMP-3 as well as the
intermediate structures along one mode direction.2.2. Docking
The diﬀerent MMP structures considered (1D8F, 1HY7, 1D5J,
1G4K) were superimposed on that of 1UEA in order to obtain the
coordinates of ligands and of the protein targets in the same orienta-
tion as 1UEA. Root mean square diﬀerences (RMSD) for the diﬀerent
pairs of structures are reported in Table 1 which shows highly similar
structures. Nevertheless, the 1UEA structure was found to be signiﬁ-
cantly diﬀerent from the others.
For each ligand, hydrogen atoms were added, charges were assigned
with Sybyl (Tripos) and a short energy minimization was achieved
using the Tripos Force ﬁeld [22].
Thereafter, all the ligands were docked into all the MMP-3 struc-
tures employing either the Flexx program [23] and its scoring function
[24,25] as available in the Sybyl graphical interface, or the Gold pro-
gram [26] using the Goldscore scoring function [27].
The ligands were docked within a sphere of 15 A˚ around the cata-
lytic zinc ion located in the active site and that participates in ligand
binding. The default parameters of the two programs were used fordocking. The 30 best solutions for each docked ligand were conserved
for analysis.
The ﬁgures were realized using VMD [28] and Pymol (Delano Sci-
entiﬁc LLC) available at http://pymol.sourceforge.net/.3. Results
To validate both Gold and Flexx docking approaches and to
examine their ability to correctly identify the ligand positions
in the MMP-3:ligands complexes, we ﬁrst docked the ligands
from 1D8F, 1HY7, 1D5J and 1G4K in their corresponding
X-ray structures, as well as in the structure of MMP-3 from
1UEA.
The ligand positions proposed by Flexx and Gold were
sorted according to their RMSD from the corresponding crys-
tallographic position of the ligands, when available. It was
observed that both methods were able to correctly predict
the position of each ligand when using its corresponding
protein X-ray structure, and also most of the other available
structures as targets (Fig. 1). However, when using 1UEA as
a target, we note that Flexx was only able to correctly replace
one ligand (1D8F) out of four, showing the limits of docking a
ligand in an inappropriate structure, even if highly related.
In the same conditions, Gold successfully replaced all four
ligands. We conclude that Gold is more permissive than Flexx
in taking into account some structure variability.
Using the crystal structure of a protein complexed with a
particular ligand as a target for docking another ligand intro-
duces a potential bias into the procedure. An unbiased docking
protocol should take the unliganded structure, if available, as
target, as in protein–protein docking predictions undertaken in
the CAPRI trials [29]. An alternative is to remove the existing
ligand and apply energy minimization or other molecular
mechanics techniques to the structure in order to partially re-
verse any ligand-induced changes.
After energy minimization of the empty 1UEA structure,
neither Flexx nor Gold was able to correctly predict the bind-
ing modes of any of the ligands. In Fig. 2A, the tube colour
and diameter represents the RMSD values obtained by com-
paring the initial and energy-minimized structures from
1UEA; this shows that the failure of the docking is probably
due to conformational diﬀerences observed in the region of
the active site (black arrows) leading to its partial closure,
especially in the region of the S1 0 hydrophobic pocket
(Fig. 2B).
A NMA was then performed on the structure of MMP-3
from 1UEA. Interestingly, it was observed that the second-
lowest-frequency vibrational mode corresponded to internal
motions describing the opening and the closure of the active
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Fig. 1. Results obtained with Flexx and Gold by docking the ligands from the diﬀerent MMP-3 PDB structures into all the X-ray structures taken as
targets, and also into the 1UEA X-ray and energy-minimized structures.
Fig. 2. Structural diﬀerences observed after energy minimization of the MMP-3 catalytic domain from 1UEA. (A) RMSD deviations with respect to
the X-ray structure represented by coloured ribbon that shows the deviations in the region of the active site (Global RMSD on heavy atoms = 1.4 A˚).
(B) Accessible surface in the region of the active site: pink meshes and the solid surface stand for the minimized and for the X-ray structures,
respectively. The MMP-3 ligands are shown as thin lines. The binding site, in particular the S1 0 pocket, can be seen to narrow after minimization.
5132 N. Floquet et al. / FEBS Letters 580 (2006) 5130–5136site of the metalloproteinase. A representation of the move-
ments of the Ca atoms of the protein along this mode is shown
in Fig. 3A. Accordingly, we further examined the potential role
of such a movement on the results of docking experiments ap-
plied to metalloproteinases.A total of 11 intermediate structures of the MMP-3 from
1UEA were then obtained for diﬀerent values of the normal
coordinate along this particular mode in the opening direction.
These structures were further used as successive targets for
docking. They corresponded to displacements ranging from
Fig. 3. (A) 2D representation of the Ca atom movements (shown with arrows) of MMP-3 from 1UEA along the second lowest-frequency mode
(3.8 cm1) corresponding to internal motions as determined by NMA and describing the opening and the closure of the active site. (B) Variations of
energies of the corresponding intermediate minimized structures under NM restraint potential with respect to the X-ray energy-minimized structure
(dr= 0 A˚).
N. Floquet et al. / FEBS Letters 580 (2006) 5130–5136 51330.0 to 1.0 A˚ with steps of 0.1 A˚ with respect to the initial X-ray
minimized structure and were obtained by energy minimiza-
tion using a restraint potential added to the internal standard
potential of the form:
k=2ðd  drÞ2
where d is the displacement along the normal mode coordinate
corresponding to the given mode (here mode 2), dr the desired
restraint distance value and k the force constant (500.000
kcal mol1 A˚2). d is deﬁned by projecting the vector of mass
weighted coordinate diﬀerences (with respect to the energy-
minimized conformation) onto the normal mode vector. Two
other restraint potentials were added corresponding to the
restriction of overall rotational and translational motions of
the molecule as described in Guilbert et al. [30].
The restraint potential allows one to obtain a series of low-
energy structures along the normal mode direction without
being limited by the harmonic approximation inherent to
NMA. Thus, the series of structures corresponded well to dif-M
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Fig. 4. Results of the docking of the ligands with Flexx and Gold in the
structure, and in the set of energy-minimized structures generated along moferent magnitudes of the opening of the cleft as described by
the mode 2. The minimizations were carried out by succes-
sively combining the SD and ABNR methods until an energy
gradient of 106 kcal mol1 A˚1 was reached. The energies
corresponding to these structures are shown in Fig. 3B. It
may be noted that reasonable energy deviations of less than
50 kcal mol1 up to about 1 A˚ displacement were observed.
By considering intermediate structures of MMP-3 along
mode 2 as targets, three out of four ligands were correctly pre-
dicted with Flexx, as shown in Fig. 4. This corresponds to a
remarkable improvement as it was impossible for Flexx to pre-
dict the correct binding modes of three out of four ligands in
the initial X-ray structure, as seen above. Moreover, for each
ligand, the best solution, as measured by the RMSD from
the crystallographic model, was found in the ten best scores
proposed by the software.
To illustrate the results obtained with Gold, we report in
Fig. 5 the best (min RMSD) position of each ligand when
docked into the X-ray energy-minimized structure fromFlexx Gold Flexx Gold
1D5J 1G4K
initial X-ray structure from 1UEA, in the corresponding minimized
de 2 in the opening direction.
Fig. 5. Graphical models of the minimum RMSD solutions proposed by Gold after the docking of the four ligands; left: in the X-ray energy-
minimized structure from the PDB 1UEA; right: in one of the intermediate structures generated along mode 2 in the opening direction. In each case,
the crystallographic solution is shown in green.
5134 N. Floquet et al. / FEBS Letters 580 (2006) 5130–51361UEA (left), and into the set of intermediate structures gener-
ated along mode 2 in the opening direction (right). The crystal-
lographic position of the ligand is shown in green. In each case,
the value of d (displacement along the mode) for which the
minimum RMSD of the ligand was found is given. With Gold,all four ligands were successfully predicted leading to results
very close to those obtained by crystallography. Thus, for
Gold, the NMA approach was not as necessary as for Flexx
when docking to the initial X-ray structure. However, the
NMA methodology considerably improved the docking results
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mized structure. Accordingly, with Gold, this approach was
particularly useful when starting from an unbiased, ligand-free
structure. Moreover, we observed that in some cases, the posi-
tion of the ligand may be slightly improved as compared to the
prediction starting with the liganded structure, as was observed
for the 1G4K ligand.4. Discussion
When the structure of a particularly interesting pharmaceu-
tical target has been resolved, ligand docking is often applied
in order to predict the binding mode of a ligand or to identify
new inhibitors from a database. Currently, such docking usu-
ally implies a ﬂexible ligand and a rigid target. Diﬃculties com-
monly arise when the ﬂexibility of the target itself is signiﬁcant.
A possible solution to overcome this ﬂexibility problem would
be to dock every ligand in each known receptor structure. In
the case of MMPs, the unliganded enzyme exhibits an active
site that is totally buried, making this structure unsuitable
for docking experiments. Additionally, for many MMPs only
one structure has been resolved; such a structure may be essen-
tially biased because it describes the target bound to a speciﬁc
ligand.
In general, both to get an unbiased structure and to be able
to apply any number of molecular modelling/molecular
mechanics techniques, the initial X-ray structure needs to be
properly energy minimized. The resulting structure is not nec-
essarily appropriate for ligand binding using existing tech-
niques. Furthermore, for most MMPs, no crystal structure is
available and the only targets are obtained by homology mod-
elling, which usually involves energy minimization and/or con-
formational sampling by molecular dynamics simulations [31].
Protein motions associated with ligand binding comprise in
general both local and global components. We show here that
NMA is very useful to explore collective movements of func-
tional relevance and thereby provide structures that can be
more appropriate for docking. On the other hand, side-chain
ﬂexibility can be suﬃcient to open binding-site cavities to
ligand access as was the case with the S1 0 cavity in MMP-1
[15]. While such local approaches will miss larger scale modiﬁ-
cations (e.g. backbone movements), the approach presented
here may underestimate local rearrangements. The local and
global approaches can be viewed as complementary in improv-
ing modelling of protein–ligand interactions.
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